https://www.live-feeds.com/feed/verastem-ceo-claims-ras-drug-has-set-a-new-benchmark-for-tricky-cancer-in-early-readoutContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/verastem-ceo-claims-ras-drug-has-set-a-new-benchmark-for-tricky-cancer-in-early-readouthttps://www.live-feeds.com/feed/verastem-ceo-claims-ras-drug-has-set-a-new-benchmark-for-tricky-cancer-in-early-readout#u130837Sun, 18 Oct 2026 06:22:18 +0000Verastem Oncology is advancing its oral KRAS G12D inhibitor, VS-7375, to Phase III trials for pancreatic cancer following positive Phase 1/2 results. In a cohort of 22 patients with metastatic pancreatic ductal adenocarcinoma receiving 900 mg daily, the drug showed a 41% response rate, including two complete responses. The company reported a 67% six-month progression-free survival and 80% overall survival for that group. To fund its pipeline, Verastem priced a $250 million offering of common stock and pre-funded warrants and appointed a new CEO.Why it mattersKRAS G12D mutations are common in d